Ethical, legal, and social issues (ELSI) in rare diseases: a landscape analysis from funders.
Clicks: 363
ID: 55127
2019
Article Quality & Performance Metrics
Overall Quality
Improving Quality
0.0
/100
Combines engagement data with AI-assessed academic quality
Reader Engagement
Star Article
85.7
/100
352 views
286 readers
Trending
AI Quality Assessment
Not analyzed
Abstract
Recent interest in personalized medicine has highlighted the importance of research in ethical, legal, and social issues (ELSI). Issues in ELSI research may be magnified in the rare diseases population (i.e., small numbers of affected individuals, challenges in maintaining confidentiality, and paucity of treatments for diseases where natural history information may be limited). More than other areas of research, potential barriers include the lack of funding opportunities and appropriate review processes for applications to funding agencies. The ELSI Working Group of the International Rare Diseases Research Consortium (IRDiRC) performed an informal survey on ELSI funding initiatives to learn more about different funding mechanisms and to identify potential gaps in funding opportunities. The Working Group discusses these challenges and highlights the role of funding agencies and partners such as patient advocacy groups, specialists in social sciences and humanities, and clinicians to advance ELSI research in rare diseases.
Abstract Quality Issue:
This abstract appears to be incomplete or contains metadata (147 words).
Try re-searching for a better abstract.
| Reference Key |
hartman2019ethicaleuropean
Use this key to autocite in the manuscript while using
SciMatic Manuscript Manager or Thesis Manager
|
|---|---|
| Authors | Hartman, Adam L;Hechtelt Jonker, Anneliene;Parisi, Melissa A;Julkowska, Daria;Lockhart, Nicole;Isasi, Rosario; |
| Journal | european journal of human genetics : ejhg |
| Year | 2019 |
| DOI |
10.1038/s41431-019-0513-3
|
| URL | |
| Keywords |
Citations
No citations found. To add a citation, contact the admin at info@scimatic.org
Comments
No comments yet. Be the first to comment on this article.